Walker Richard I
Division of Bacterial, Parasitic and Allergenic Products, US Food and Drug Administration, 1401 Rockville Pike (HFM-425), Rockville, MD20651-1448, USA.
Expert Rev Vaccines. 2005 Dec;4(6):807-12. doi: 10.1586/14760584.4.6.807.
Diarrheal diseases represent a major threat to infant survival in less developed countries. A real opportunity now exists to help alleviate this problem through the development of safe and effective multicomponent whole-bacterial cell vaccine(s) against enterotoxigenic Escherichia coli and Shigella, two important pathogens for which no licensed vaccine exists. What is preventing realization of this achievement is a lack of focus on the unique needs of children in less developed countries, along with committed and sufficient funding directed toward this goal. Live-attenuated and inactivated whole-cell vaccine candidates, some of which have languished too long, are available for testing, which, if performed in a coordinated fashion, can answer key unresolved issues concerning mucosal vaccination against enteric diseases. These candidate vaccines potentially provide a relatively simple intervention which could, if implemented, reduce the impact of these diseases upon the life and productivity of children.
腹泻病对欠发达国家的婴儿生存构成重大威胁。目前存在一个切实的机会，可通过研发针对产肠毒素大肠杆菌和志贺氏菌的安全有效的多组分全细菌细胞疫苗来帮助缓解这一问题，这两种重要病原体目前尚无获批疫苗。阻碍实现这一成果的是缺乏对欠发达国家儿童独特需求的关注，以及缺乏针对这一目标的坚定且充足的资金投入。减毒活疫苗和灭活全细胞候选疫苗已经可以用于测试，其中一些已经搁置太久，如果以协调的方式进行测试，能够解答有关肠道疾病黏膜疫苗接种的关键未解决问题。这些候选疫苗有可能提供一种相对简单的干预措施，如果实施，可减少这些疾病对儿童生活和生产力的影响。
